Also found in: Dictionary, Thesaurus.
Related to Fortovase: Invirase


A trademark for the drug saquinavir.
References in periodicals archive ?
The efficacy of INVIRASE with ritonavir or Fortovase (with or without ritonavir coadministration) has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.
When using saquinavir as the sole protease inhibitor in an antiviral regimen, Fortovase is the recommended formulation.
COLUMN A COLUMN B Agenerase Retrovir plus Hivid Fortovase Videx plus Epivir Norvir Rescriptor Viracept plus Fortovase Viramune Ziagen
INVIRASE and FORTOVASE are trademarks of Hoffmann-LaRoche Inc.
INVIRASE will remain on the market in both 500 mg tablets and 200 mg capsules, while FORTOVASE will be discontinued during the first quarter of 2006.
The new INVIRASE 500 mg tablet offers patients key advantages over FORTOVASE, including lower bill burden, improved gastrointestinal tolerability, smaller capsule/tablet size and no need for refrigeration.
Cholesterol and triglyceride levels should be monitored prior to initiating combination dosing regimen of Fortovase or Invirase with ritonavir, and at periodic intervals while on such therapy.
The following grade 2 to grade 4 adverse events (all causality) occurred in at least two percent of patients receiving Fortovase with ritonavir (1000/100 mg twice daily): abdominal pain, back pain, bronchitis, constipation, diabetes mellitus/hyperglycemia, diarrhea, dry lips/skin, eczema, fatigue, fever, influenza, lipodystrophy, nausea, pneumonia, pruritis, rash, sinusitis, and vomiting.
INVIRASE capsules do not require refrigeration and are smaller in size than Fortovase capsules.
It is important to note that INVIRASE and Fortovase are not bioequivalent and cannot be used interchangeably.
This new tablet could replace the existing Fortovase and Invirase capsules and encourage adherence by improving convenience.